Key points
- Azer-cel, Imugene's off-the-shelf CAR T therapy, continues to show promising clinical results across multiple cohorts.
- FDA granted Fast Track Designation to azer-cel for two additional indications: CLL/SLL and MZL.
- The company raised approximately $52 million in funding rounds and received a $2.7 million R&D tax refund.
- Discontinued earlier technologies to focus on azer-cel, the lead asset.
- Reported a net loss of $105.3 million for the financial year.
Full summary
Imugene Ltd's Annual Report for the year ended 30 June 2026 highlights significant progress in the development of azer-cel, an off-the-shelf CAR T therapy targeting CD19 for blood cancers. The company reported encouraging data from its Phase 1b clinical trial, including an 82% overall response rate in relapsed/refractory DLBCL patients. Additionally, azer-cel demonstrated promising results in CAR T naive patients and those treated concurrently with BTK inhibitors. The FDA granted Fast Track Designation for two additional indications: CLL/SLL and MZL. The company raised approximately $52 million in funding rounds and received a $2.7 million R&D tax refund. Imugene also discontinued earlier technologies to focus on azer-cel, which has the clearest clinical and regulatory path to patients. The company reported a net loss of $105.3 million for the financial year.
Guidance
Net loss of $105.3 million for the financial year
Outlook
Imugene plans to advance azer-cel into a pivotal study and continue to focus on its development as the lead asset.